Is B-cell–depleting therapy more efficacious than calcineurin inhibition in maintaining relapse-free survival in children with corticosteroid-dependent nephrotic syndrome?
In this randomized clinical trial that included 120 children with corticosteroid-dependent nephrotic syndrome, a single course of rituximab therapy was associated with a significantly higher 12-month relapse-free survival rate than daily tacrolimus therapy (90.0% vs 63.3%) during 12 months of follow-up. The mean cumulative corticosteroid dose during the 12-month study period was lower with rituximab compared with tacrolimus (25.8 vs 86.3 mg/kg).
In children with corticosteroid-dependent nephrotic syndrome, rituximab is more effective than tacrolimus in maintaining disease remission and may be considered as first-line corticosteroid-sparing therapy.
Calcineurin inhibitors are an established first-line corticosteroid-sparing therapy for patients with corticosteroid-dependent nephrotic syndrome (CDNS), whereas B-lymphocyte–depleting therapy is mostly used as a rescue for calcineurin inhibitor–resistant cases. The positive efficacy and safety profile of rituximab raises the question of whether it could be used as a first-line alternative to calcineurin inhibitor therapy.
To compare the efficacy of rituximab and tacrolimus in maintaining relapse-free survival among children with CDNS.
Design, Setting, and Participants
A parallel-arm, open-label, randomized clinical trial was performed from May 8, 2015, to September 20, 2016, with 1-year follow-up in a single-center, tertiary care unit. A total of 176 consecutive children aged 3 to 16 years with CDNS not previously treated with corticosteroid-sparing agents were screened for eligibility.
The children received either tacrolimus (along with tapering alternate-day prednisolone) for 12 months or a single course of rituximab (2 infusions of 375 mg/m2).
Main Outcomes and Measures
Twelve-month relapse-free survival in the intention-to-treat population.
Of the 176 children screened for eligibility, 120 were randomized and all but 3 patients completed 1 year of follow-up. The groups were comparable, with mean (SD) age of 7.2 (2.8) years, 32 boys (53.3%) in each group, mean (SD) disease duration of 2.5 (1.5) years and 2.3 (1.7) in the tacrolimus and rituximab groups, respectively, disease duration less than 1 year among 15 children (25.0%) in each group, median (interquartile range) of 4 (3-5) relapses in each group, and mean (SD) cumulative prednisolone dose of 246 (48) mg/kg and 239 (52) mg/kg in the prestudy year in the tacrolimus and rituximab groups, respectively. Rituximab therapy was associated with a higher 12-month relapse-free survival rate than tacrolimus (54 [90.0%] vs 38 [63.3%] children; P < .001; odds ratio, 5.21; 95% CI, 1.93-14.07). Among the patients who experienced relapse, median time to first relapse was 40 weeks in the rituximab group and 29 weeks in the tacrolimus group. Only 2 patients in the rituximab group had more than 1 relapse during the study period compared with 10 patients in the tacrolimus group. The cumulative corticosteroid dose during the 12-month study period was lower with rituximab compared with tacrolimus (mean [SD], 25.8 [27.8] vs 86.3 [58.0] mg/kg). Although both treatments were well tolerated, mild to moderate infections were twice as common in the tacrolimus group (26 [43.3%] vs 13 [21.7%] events).
Conclusions and Relevance
In children with CDNS, rituximab appears to be more effective than tacrolimus in maintaining disease remission and minimizing corticosteroid exposure and, given its good tolerability and lack of nephrotoxic effects, may be considered as first-line corticosteroid-sparing therapy.
ClinicalTrials.gov Identifier: NCT02438982; Clinical Trial Registry of India: CTRI/2014/01/004355
Basu B, Sander A, Roy B, et al. Efficacy of Rituximab vs Tacrolimus in Pediatric Corticosteroid-Dependent Nephrotic Syndrome: A Randomized Clinical Trial. JAMA Pediatr. 2018;172(8):757–764. doi:10.1001/jamapediatrics.2018.1323
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: